Top

Published in:

01-03-2021 | Hepatocellular Carcinoma | Case Report

Large Multifocal Hepatocarcinoma: Technical Details of Treatment with Combined Transarterial Chemoembolization, Microwave and Radiofrequency Ablation

Authors: Enrico Boninsegna, Emilio Simonini, Stefano Crosara, Michela De Angelis, Luigi Boccia, Stefano Colopi

Published in: Journal of Gastrointestinal Cancer | Issue 1/2021

Excerpt

Percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA) for the treatment of hepatocellular carcinoma (HCC) have shown excellent therapeutic efficacies, often comparable with those of surgical resection [1‐3]. Combined transarterial chemoembolization (TACE) and percutaneous ablations (RFA/MWA) were first introduced as strategies to obtain a larger treatment zone during ablation procedures [4]. The efficacy of a combined approach has been proven for small- and medium-sized HCCs [1, 5‐7]; in addition, TACE-RFA/MWA can be applied for the treatment of small HCCs inconspicuous on ultrasound (US) or unenhanced computed tomography (CT), two guiding modalities for minimally invasive ablation procedures [2, 8]. The efficacy of combined TACE and percutaneous technologies for large hepatocellular carcinoma in patients not suitable for surgical resection has not yet been proven [9]. We report two cases of a giant multifocal hepatocarcinoma, successfully treated with combined TACE-MWA and TACE-RFA. …

Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol. 2005;39(3):247–52. https://doi.org/10.1097/01.mcg.0000152746.72149.31.CrossRefPubMed

Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol. 2018;24(4):219–24. https://doi.org/10.5152/dir.2018.17528.CrossRefPubMedPubMedCentral

Zheng L, Zhang CH, Lin JY, Song CL, Qi XL, Luo M. Comparative effectiveness of radiofrequency ablation vs. surgical resection for patients with solitary hepatocellular carcinoma smaller than 5 cm. Frontiers in Oncology. 2020;10:399. https://doi.org/10.3389/fonc.2020.00399.CrossRefPubMedPubMedCentral

Koda M, Ueki M, Maeda Y, Mimura KI, Okamoto K, Matsunaga Y, et al. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res. 2004;29(1):18–23. https://doi.org/10.1016/j.hepres.2004.02.001.CrossRefPubMed

Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81(3):e189–93. https://doi.org/10.1016/j.ejrad.2011.01.122.CrossRefPubMed

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60. https://doi.org/10.1002/cncr.25314.CrossRefPubMed

Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008;247(1):260–6. https://doi.org/10.1148/radiol.2471070818.CrossRefPubMed

Ni JY, Fang ZT, Sun HL, An C, Huang ZM, Zhang TQ, et al. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Eur Radiol. 2020;30(4):2377–90. https://doi.org/10.1007/s00330-019-06438-8.CrossRefPubMed

Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, et al. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(8):7407–13. https://doi.org/10.1007/s13277-014-1976-z.CrossRef

10.

Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Journal of vascular and interventional radiology : JVIR. 2009;20(7 Suppl):S377–90. https://doi.org/10.1016/j.jvir.2009.04.011.CrossRefPubMed

11.

Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2014;20(35):12588–94. https://doi.org/10.3748/wjg.v20.i35.12588.CrossRefPubMedPubMedCentral

Title: Large Multifocal Hepatocarcinoma: Technical Details of Treatment with Combined Transarterial Chemoembolization, Microwave and Radiofrequency Ablation
Authors: Enrico Boninsegna
Emilio Simonini
Stefano Crosara
Michela De Angelis
Luigi Boccia
Stefano Colopi
Publication date: 01-03-2021
Publisher: Springer US
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Journal of Gastrointestinal Cancer / Issue 1/2021
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-020-00416-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Expression Profile of miRNA-17-3p and miRNA-17-5p Genes in Gastric Cancer Patients with Helicobacter pylori Infection

Prevalence of Mismatch Repair-Deficient Colorectal Adenoma/Polyp in Early-Onset, Advanced Cases: a Cross-Sectional Study Based on Iranian Hereditary Colorectal Cancer Registry

TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer

Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era

ACE Inhibitor Therapy Does Not Influence the Survival Outcomes of Patients with Colorectal Liver Metastases Following Liver Resection

An Uncommon Polyp of the Right Colon: an Unusual Presentation of Melanoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials